Search

Your search keyword '"Chaudhuri, Sujit"' showing total 9 results
Start Over Author "Chaudhuri, Sujit" Publication Year Range Last 3 years
9 results on '"Chaudhuri, Sujit"'

2. Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology

Author

Ghoshal, Uday C., Sachdeva, Sanjeev, Pratap, Nitesh, Karyampudi, Arun, Mustafa, Uzma, Abraham, Philip, Bhatt, Chetan B., Chakravartty, Karmabir, Chaudhuri, Sujit, Goyal, Omesh, Makharia, Govind K., Panigrahi, Manas Kumar, Parida, Prasanta Kumar, Patwari, Sudhanshu, Sainani, Rajesh, Sadasivan, Shine, Srinivas, M., Upadhyay, Rajesh, and Venkataraman, Jayanthi

Published
2023
Full Text
View/download PDF

4. Helicobacter pylori attachment-blocking antibodies protect against duodenal ulcer disease

Author

Boren, Thomas, primary, Bugaytsova, Jeanna A., additional, Moonens, Kristof, additional, Piddubnyi, Artem, additional, Schmidt, Alexej, additional, Edlund, Johan Olofsson, additional, Lisiutin, Gennadii, additional, Brannstrom, Kristoffer, additional, Chernov, Yevgen A., additional, Thorell, Kaisa, additional, Tkachenko, Iryna, additional, Sharova, Oleksandra, additional, Vikhrova, Iryna, additional, Butsyk, Anna, additional, Shubin, Pavlo, additional, Chyzhma, Ruslana, additional, Johansson, Daniel X., additional, Marcotte, Harold, additional, Sjostrom, Rolf, additional, Shevtsova, Anna, additional, Bylund, Goran, additional, Rakhimova, Lena, additional, Lundquist, Anders, additional, Berhilevych, Oleksandra, additional, Kasianchuk, Victoria, additional, Loboda, Andrii, additional, Ivanytsia, Volodymyr, additional, Hultenby, Kjell, additional, Persson, Mats A. A., additional, Gomes, Joana, additional, Matos, Rita, additional, Gartner, Fatima, additional, Reis, Celso A., additional, Whitmire, Jeannette M., additional, Merrell, Douglas Scott, additional, Pan-Hammarstrom, Qiang, additional, Landstrom, Marene, additional, Oscarson, Stefan, additional, DElios, Mario M., additional, Agreus, Lars, additional, Ronkainen, Jukka, additional, Aro, Pertti, additional, Engstrand, Lars, additional, Graham, David Y., additional, Kachkovska, Vladyslava, additional, Mukhopadhyay, Asish, additional, Chaudhuri, Sujit, additional, Karmakar, Bipul Chandra, additional, Paul, Sangita, additional, Kravets, Oleksandr, additional, Camorlinga-Ponce, Margarita, additional, Torres, Javier, additional, Berg, Douglas E., additional, Moskalenko, Roman, additional, Haas, Rainer, additional, Remaut, Han, additional, and Hammarstrom, Lennart, additional

Published
2023
Full Text
View/download PDF

7. Region-specific genomic signatures of multidrug-resistant Helicobacter pylori isolated from East and South India

Author

Kumar, Shakti, primary, Mehrotra, Tanshi, additional, Talukdar, Daizee, additional, Verma, Jyoti, additional, Chandra Karmakar, Bipul, additional, Paul, Sangita, additional, Chaudhuri, Sujit, additional, Kumari Pragasam, Agila, additional, Bakshi, Susmita, additional, Kumari, Shashi, additional, Chawla, Meenal, additional, Purohit, Ayushi, additional, Porey Karmakar, Sonali, additional, Mutreja, Ankur, additional, Banerjee, Sayantan, additional, Ray, Animesh, additional, Ramamurthy, Thandavarayan, additional, Mukhopadyay, Asish K, additional, and Das, Bhabatosh, additional

Published
2022
Full Text
View/download PDF

8. Helicobacter pylori attachment-blocking antibodies protect against duodenal ulcer disease.

Author

Bugaytsova JA, Moonens K, Piddubnyi A, Schmidt A, Edlund JO, Lisiutin G, Brännström K, Chernov YA, Thorel K, Tkachenko I, Sharova O, Vikhrova I, Butsyk A, Shubin P, Chyzhma R, Johansson DX, Marcotte H, Sjöström R, Shevtsova A, Bylund G, Rakhimova L, Lundquist A, Berhilevych O, Kasianchuk V, Loboda A, Ivanytsia V, Hultenby K, Persson MAA, Gomes J, Matos R, Gartner F, Reis CA, Whitmire JM, Merrell DS, Pan-Hammarström Q, Landström M, Oscarson S, D'Elios MM, Agreus L, Ronkainen J, Aro P, Engstrand L, Graham DY, Kachkovska V, Mukhopadhyay A, Chaudhuri S, Karmakar BC, Paul S, Kravets O, Camorlinga M, Torres J, Berg DE, Moskalenko R, Haas R, Remaut H, Hammarström L, and Borén T

Abstract

The majority of the world population carry the gastric pathogen Helicobacter pylori . Fortunately, most individuals experience only low-grade or no symptoms, but in many cases the chronic inflammatory infection develops into severe gastric disease, including duodenal ulcer disease and gastric cancer. Here we report on a protective mechanism where H. pylori attachment and accompanying chronic mucosal inflammation can be reduced by antibodies that are present in a vast majority of H. pylori carriers. These antibodies block binding of the H. pylori attachment protein BabA by mimicking BabA's binding to the ABO blood group glycans in the gastric mucosa. However, many individuals demonstrate low titers of BabA blocking antibodies, which is associated with an increased risk for duodenal ulceration, suggesting a role for these antibodies in preventing gastric disease., Competing Interests: DECLARATION OF INTERESTS The authors declare the following competing interests: T. Borén and L. Hammarström are founders of Helicure AB and, own the IP-rights to the anti-BabA ABbA-IgG1 (US patent US8025880B2) and own the IP-rights to the gastric cancer vaccine and diagnostics described in the two manuscripts by Bugaytsova et al., 2023 (Patent Application SE 2350423-6).

Published
2023
Full Text
View/download PDF

9. Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium.

Author

Banerjee R, Pal P, Hilmi I, Ghoshal UC, Desai DC, Rahman MM, Dutta U, Mohiuddin SA, Al Mohannadi M, Philip M, Ramesh GN, Niriella MA, De Silva AP, de Silva HJ, Pisespongsa P, Limsrivilai J, Aniwan S, Nawarathne M, Fernandopulle N, Aye TT, Ni N, Al Awadhi S, Joshi N, Ngoc PTV, Kieu TV, Nguyen AD, Abdullah M, Ali E, Zeid A, Sollano JD, Saberi B, Omar M, Mohsin MN, Aftab H, Wai TM, Shastri YM, Chaudhuri S, Ahmed F, Bhatia SJ, and Travis SPL

Subjects
Aged, Asia, Southeastern, Cross-Sectional Studies, Delayed Diagnosis, Asia, Eastern, Female, Humans, Immunologic Factors, Incidence, Male, Mesalamine, Phenotype, Colitis, Ulcerative diagnosis, Colitis, Ulcerative epidemiology, Colitis, Ulcerative therapy, Crohn Disease diagnosis, Crohn Disease drug therapy, Crohn Disease epidemiology, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy
Abstract

Background and Aim: Inflammatory bowel disease (IBD) is emerging in the newly industrialized countries of South Asia, South-East Asia, and the Middle East, yet epidemiological data are scarce., Methods: We performed a cross-sectional study of IBD demographics, disease phenotype, and treatment across 38 centers in 15 countries of South Asia, South-East Asia, and Middle East. Intergroup comparisons included gross national income (GNI) per capita., Results: Among 10 400 patients, ulcerative colitis (UC) was twice as common as Crohn's disease (CD), with a male predominance (UC 6678, CD 3495, IBD unclassified 227, and 58% male). Peak age of onset was in the third decade, with a low proportion of elderly-onset IBD (5% age > 60). Familial IBD was rare (5%). The extent of UC was predominantly distal (proctitis/left sided 67%), with most being treated with mesalamine (94%), steroids (54%), or immunomodulators (31%). Ileocolic CD (43%) was the commonest, with low rates of perianal disease (8%) and only 6% smokers. Diagnostic delay for CD was common (median 12 months; interquartile range 5-30). Treatment of CD included mesalamine, steroids, and immunomodulators (61%, 51%, and 56%, respectively), but a fifth received empirical antitubercular therapy. Treatment with biologics was uncommon (4% UC and 13% CD), which increased in countries with higher GNI per capita. Surgery rates were 0.1 (UC) and 2 (CD) per 100 patients per year., Conclusions: The IBD-ENC cohort provides insight into IBD in South-East Asia and the Middle East, but is not yet population based. UC is twice as common as CD, familial disease is uncommon, and rates of surgery are low. Biologic use correlates with per capita GNI., (© 2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results